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ARTICLE
Hsp70 and Hsp40 inhibit an inter-domain
interaction necessary for transcriptional activity
in the androgen receptor
Bahareh Eftekharzadeh1,2,7, Varuna C. Banduseela3,7, Giulio Chiesa1,2,7, Paula Martínez-Cristóbal1,2,7,
Jennifer N. Rauch4, Samir R. Nath3, Daniel M.C. Schwarz4, Hao Shao4, Marta Marin-Argany1,2,
Claudio Di Sanza1,2, Elisa Giorgetti 3, Zhigang Yu3, Roberta Pierattelli 5, Isabella C. Felli 5,
Isabelle Brun-Heath1,2, Jesús García 1, Ángel R. Nebreda1,6, Jason E. Gestwicki 4, Andrew P. Lieberman3 &
Xavier Salvatella 1,2,6
Molecular chaperones such as Hsp40 and Hsp70 hold the androgen receptor (AR) in an
inactive conformation. They are released in the presence of androgens, enabling transacti-
vation and causing the receptor to become aggregation-prone. Here we show that these
molecular chaperones recognize a region of the AR N-terminal domain (NTD), including a
FQNLF motif, that interacts with the AR ligand-binding domain (LBD) upon activation. This
suggests that competition between molecular chaperones and the LBD for the FQNLF motif
regulates AR activation. We also show that, while the free NTD oligomerizes, binding to
Hsp70 increases its solubility. Stabilizing the NTD-Hsp70 interaction with small molecules
reduces AR aggregation and promotes its degradation in cellular and mouse models of the
neuromuscular disorder spinal bulbar muscular atrophy. These results help resolve the
mechanisms by which molecular chaperones regulate the balance between AR aggregation,
activation and quality control.
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Molecular chaperones are key components of the proteinquality control system. In addition to their well-knownroles in protein folding and degradation1,2, they also
stabilize specific conformations of proteins to enable the fast and
efficient relay of signaling information. This aspect of their
function is exemplified by their activity on steroid hormone
receptors (SHRs), such as the glucocorticoid receptor (GR) and
the androgen receptor (AR). It is known that a complex of heat
shock proteins, including Hsp90, Hsp70, HOP, and Hsp40, is
required to stabilize an inactive SHR conformation3,4. This
activity is termed a holdase function because the apo-receptor is
held in a structural state that is stable, soluble and prepared for
binding to ligands5. Hormone binding then shifts the SHR into a
distinct conformer of lower solubility that gains affinity for DNA
and is capable of activating transcription. Intriguingly, at least
some of the members of the chaperone machinery become more
transiently associated with the SHR during this process6, sug-
gesting that these complexes are dynamic and play a role in
stabilizing the conformation of the active receptor. In addition, a
subset of the chaperones, including Hsp70, is also required for
SHR turnover, through recruitment of E3 ubiquitin ligases7.
Thus, the SHR system provides an excellent model for under-
standing how molecular chaperones balance the needs of protein
folding, stability, function and quality control.
Pioneering studies by Pratt et al. have revealed the order of
chaperone binding and release from SHRs3,4 and defined the
importance of their individual functions in cell-free systems and
in cells8. In support of this notion, a recent study showed that
Hsp70, HOP, and Hsp90 bind to the ligand-binding domain
(LBD) of GR9, holding it in a stable, open conformation. How-
ever, it is unknown whether this mechanism is conserved in other
nuclear receptors; indeed, the Buchner group recently found that
different Hsp90 co-chaperones are required for activating GR
when compared to AR10. In addition the structural roles of the
chaperones during SHR activation and turnover are also not
clear: for example, it has been proposed that Hsp70 interactions
with the LBD are involved in receptor triage11,12, but chemical
modulators of Hsp70 or Hsp40 induce ubiquitin-dependent
degradation of AR variants that lack the LBD13. These observa-
tions suggest that some chaperones, especially Hsp70 and Hsp40,
may have additional binding sites outside the canonical LBD
region and that these might be critical for homeostasis of
some SHRs.
A mechanistic knowledge of how SHRs are regulated by
chaperones is also important for better understanding their
roles in disease. For example, AR is an important therapeutic
target for prostate cancer, because it controls the expression of
genes associated with proliferation14,15 in response to andro-
gens, such as dihydrotestosterone (DHT)16. AR is also clinically
important in spinal and bulbar muscular atrophy (SBMA), a
progressive degenerative disorder of the neuromuscular system
caused by the pathologic expansion of a polyglutamine (polyQ)
tract in the disordered, N-terminal domain of AR17. In vitro
and in cells, polyQ repeats beyond 37 residues in length cause
hormone-dependent AR misfolding and aggregation. In
patients and animal models, this misfolding manifests through
the formation of nuclear inclusions in motor neurons and
skeletal muscle cells that contain ubiquitinated and misfolded
polyQ AR18,19. Importantly, the chaperone-bound form of
polyQ AR appears to be protected from aggregation, such that it
only becomes insoluble after androgen-mediated release of the
chaperones. Together, these findings in prostate cancer and
SBMA have created particular interest in understanding the
molecular mechanisms of how chaperones control the solubi-
lity, activation and turnover of AR8,12,20,21. Such discoveries
could lead to new therapeutics: for example, it has recently been
shown that chemical activators of Hsp70 regulate the tran-
scriptional activity of AR22,23.
AR is a 919-residue protein composed of three domains: the N-
terminal transactivation domain (NTD; residues 1–558), the
central DNA-binding domain (DBD; 559-619) and the C-
terminal LBD (669–919). The structures of the DBD and LBD
bound to their ligands have been characterized by X-ray crys-
tallography24–27. The NTD is intrinsically disordered28, but
solution nuclear magnetic resonance (NMR) spectroscopy has
shown that it is rich in secondary structure, especially in regions
key for transactivation29,30. The NTD of AR is one of the longest
in the human SHR family and it includes the polyQ tract, starting
at residue 58, which becomes expanded in SBMA17. Binding of
androgens to the LBD causes a large conformational change that
leads to the nuclear localization of the receptor, driven by
exposure of a nuclear localization signal between the DBD and
the LBD16. Despite its relevance for both transcriptional activity
and the onset of SBMA, the nature of this conformational change
is not yet well-established. Nonetheless, it is known that androgen
binding exposes a hydrophobic patch in the LBD, termed acti-
vation function 2 (AF-2), that has high affinity for a 5-residue
FQNLF motif in the N-terminal segment of the NTD31. The
inter-domain interaction between this highly conserved motif and
AF-2 has been characterized by various biophysical methods,
including X-ray crystallography. These studies show that FQNLF
binds to the LBD as an α-helix32, but it is not clear why this
conformational transition is also associated with the disassembly
of the chaperone complex. It has been proposed that, similar to
GR9, molecular chaperones bind to the LBD of AR and that their
affinities for it decrease upon interaction with DHT, but the
mechanisms underlying this regulation are unknown.
To investigate the earliest stages of AR activation by androgens,
we analyzed the interaction of Hsp70 and Hsp40 with the NTD of
AR in vitro, by solution NMR33, and in cells. Solution NMR is
particularly well-suited to the characterization of transient
protein–protein interactions (PPIs) involving disordered
domains34. We found that Hsp70 and Hsp40 bind the NTD, with
µM affinity and, strikingly, that the binding site contains the same
FQNLF motif that interacts with AF-2 in the LBD during acti-
vation. This observation suggests a tug-of-war model in which the
FQNLF motif can be bound by either chaperone or the LBD, such
that hormone binding shifts partitioning between these two
possibilities. In addition, we found that this part of the NTD has
the propensity to form oligomers that are stabilized by interac-
tions involving residues of the FQNLF motif, leading to aggre-
gation; however its interaction with Hsp70 keeps the protein in
solution, explaining why chaperones are so well positioned to
block the aggregation and misfolding of AR. Given that Hsp40,
Hsp70, and other chaperones bind near polyQ repeats in other
proteins such as huntingtin this suggests a general
mechanism35,36 by which these molecular chaperones keep pro-
teins harboring polyQ tracts soluble. Inspired by these findings,
we used small molecules to stabilize the interactions of Hsp70
with AR containing an expanded polyQ tract in cellular and
mouse models of SBMA. Consistent with the results of the bio-
physical studies, these treatments reduce aggregation and
enhance clearance of polyQ-expanded AR. Our results thus
provide a structural basis for how chaperones manage the stabi-
lity, activation, solubility and turnover of AR, which should
inform efforts to treat both prostate cancer and SBMA.
Results
Hsp70 and Hsp40 bind to the FQNLF motif in the AR NTD.
We used solution NMR to determine whether Hsp40 and Hsp70
bind to the NTD of AR and, if so, where this interaction occurs.
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This study took advantage of recent reports that characterized
two NTD constructs (NTD1-155 and NTD144-450) in solution26,29.
Briefly, NTD1-155 contains the FQNLF motif and the polymorphic
polyQ repeat associated with SBMA, and spans residues 1–155
according to numbering used in the AR entry in the Uniprot
database (http://www.uniprot.org/uniprot/P10275); the version of
NTD1-155 that we used contains 25 residues in the polyQ repeat,
unlike the sequence found in Uniprot, that contains 23 (Fig. 1a).
NTD144-450 contains the regions of the NTD involved in inter-
actions with transcription factors and transcriptional co-reg-
ulators, termed activation function 1 (AF-1)29,30. We incubated
NTD1-155 (33 µM) or NTD144-450 (33 µM) with either 0.5 or 1
molar equivalents of human Hsp70 (HSPA1A) or Hsp40
(DNAJA2). These experiments were performed in the absence of
added nucleotides and samples were held at 5 °C, a temperature
that maximizes spectral quality. The 1H,15N-HSQC spectrum of
NTD144-450 was not altered by the addition of either Hsp40 or
Hsp70, indicating weak or no interaction (Supplementary Fig. 1).
This result is important because NTD144-450 includes hydro-
phobic motifs that could represent non-specific sites for chaper-
one binding, yet none were observed to interact under these
conditions. By contrast, some signals in the spectrum of NTD1-155
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Fig. 1 Hsp40 and Hsp70 interact with a region of the NTD containing the FQNLF motif. a Domain organization of the androgen receptor with an indication,
in gray, of the regions of sequence of the transactivation domain (NTD) that are partially folded, of the structures of the globular domains (DBD and LBD)
and of the two constructs used in this work (NTD1-155 and NTD144-450)26,29. b Changes in the intensity of the resonances of 33 μM NTD1-155 caused by 0.5
(orange for Hsp40, red for Hsp70) and 1 (blue for Hsp40, green for Hsp70) molar equivalents of Hsp40 (top) and Hsp70 (bottom), in the absence of
added nucleotides, with an indication of the accessible area buried upon folding (AABUF)42, of the disorder propensity as predicted by PONDR69, and of
the interaction motif identified in this work, where positively charged residues are shown in blue, hydrophobic residues are shown in green and the residues
labeled with a black dot are shown in c. c Selected regions of the 1H,15N-HSQC spectrum of 33 μM NTD1-155 in the presence of 0.5 and 1 molar equivalents
of Hsp40 (top) and Hsp70 (bottom), in the absence of added nucleotides, that illustrate that no chemical shift changes are observed upon interaction with
Hsp40 and Hsp70. In c only the contour of lowest intensity is shown for clarity, colored according to the code used in b
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decreased in intensity (I/I0 ~ 0.3 at [Hsp]/[NTD1-155]= 1) with-
out changing their position in the spectra (Fig. 1b, c). This result
indicates that the chaperones interact selectively with a region
within NTD1-155. We found that the states populated under these
conditions - the free state and, likely, various bound states37 - are
in intermediate-to-slow exchange on the NMR timescale. The low
temperature used to carry out these experiments (5 °C) might
contribute to the low observed exchange rate. Also this scenario is
typical for chaperone binding38,39 and suggests a dissociation
constant lower than the concentration used in the experiments i.e.
in the low micro molar range (see below).
In these experiments, clear decreases in signal intensities
were observed in the first 35 residues of NTD1-155, which,
strikingly, includes the motif FQNLF; this motif forms a
complex with the LBD after activation by androgens31,32. We
observed similar changes for Hsp70 and Hsp40, which is
consistent with the known similarity of consensus sites for these
two chaperones (see below)40,41. In addition, we observed much
smaller decreases in signal intensity in other residues of NTD1-
155 likely caused by transient interactions. For example,
intensity changes were observed in the hydrophobic 55LLLL58
motif that induces a helical structure in the polyQ tract of
AR26,27. In summary we found that, prior to activation by
androgens, Hsp70 and Hsp40 bind to the NTD of AR by
selectively interacting with a short region that includes the
FQNLF motif.
To determine whether this motif is an important part of the
region that binds to Hsp40 and Hsp70, we produced a mutant
NTD1-155, named AQNAA-NTD1-155, in which residues Phe 24,
Leu 27 and Phe 28 were mutated to Ala. These mutations were
predicted to decrease the hydrophobicity of the putative binding
site, expressed as AABUF42 (Supplementary Fig. 2A), a property
that is key for the ability of these molecular chaperones to
recognize their substrates37,43. By NMR, neither Hsp40 nor
Hsp70 interacted with AQNAA-NTD1-155, confirming that the
FQNLF motif is indeed important for the interaction between
these molecular chaperones and this region of AR (Supplemen-
tary Fig. 2A).
There are two possible regions of Hsp70 where substrates bind
to: a canonical site in a hydrophobic groove in the substrate
binding domain (SBD) and a non-canonical interaction surface44.
To test which site was used by AR’s NTD1-155 we titrated it into
solutions of Hsp70SBD (residues 394 to 509) and measured
competition for a model, canonical peptide (LVEALY-FAM) by
fluorescence polarization (FP) in the absence of nucleotides. We
found that NTD1-155 competed with LVEALY-FAM (Fig. 2), even
better than the NR peptide, a bona fide Hsp70 substrate,
suggesting that it bound with an IC50 1.7 ± 0.5 µM to the
canonical binding site. We repeated these experiments by using
the AQNAA-NTD1-155 mutant and found, in agreement with the
NMR experiments, that it had ~10-fold weaker affinity for Hsp70
(Supplementary Fig. 3). To further verify this interaction by an
independent method, we measured the affinity between NTD1-155
and Hsp70 by isothermal titration calorimetry (ITC). Although it
was challenging to quantify the affinity because of solubility
limitations, the binding affinity was estimated to be ~5 µM
(Fig. 2b). This value is in good agreement with the FP studies as
well as with the NMR titrations because this dissociation constant
should lead, in the slow exchange regime, to I/I0 ~ 0.3 when the
NTD1-155 (at 33 µM) is in the presence of an equimolar amount of
molecular chaperone (see Fig. 1b). Together, these results suggest
that the region of sequence corresponding to the FQNLF motif of
AR and its flanking regions represents a canonical substrate for
Hsp70.
As mentioned above, Hsp40 and Hsp70 often compete for the
same sites on their client proteins. To understand the relative
affinities of these chaperones, we measured binding of purified,
human Hsp40 (DnaJA2) for NTD1-155 by ITC. Hsp40 bound
slightly tighter to NTD1-155, with a Kd of 3.3 ± 2.3 µM
(Supplementary Fig. 3B). The stoichiometry of the complex was
estimated to be ~2 Hsp40s per NTD1-155, (n= 0.49 ± 0.27)
0.01 0.1 1 10 100
0
50
100
NR
NTD1–155
Substrate/μM
a
D
el
ta
 m
P
LVEALY-FAM
b
Molar ratio
Po
w
er
/μ
ca
l.s
–
1
ΔH
/k
ca
l.m
ol
–
1
t/min
0
0.00
–0.10
–0.20
–0.30
–0.40
–0.50
0.00
–2.00
–4.00
0.0 0.5 1.0 1.5 2.0
10 20 30 40 50
Fig. 2 The FQNLF motif binds to the canonical binding site in Hsp70 in the
absence of nucleotides. a Binding of NTD1-155to the canonical cleft of
Hsp70SBD at 2 μM in the absence of nucleotides was measured by
competition with the canonical peptide LVEAVY labelled with a FAM
fluorophore (25 nM) as measured by FP. NR, a bona fide substrate of
Hsp70SBD, was used as positive control. Data are the average of at least
three independent experiments performed in duplicate on different days
and the error bars represent S.E.M. b Direct binding of NTD1-155 to
Hsp70SBD in the absence of nucleotides was measured by ITC: the top
panel represents the raw data whereas the lower panel represents the
integrated heat peaks and the fit to the one-site binding model. Source data
for a are available as Source Data file
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consistent with the dimeric structure of this chaperone. These
results suggest that both Hsp70 and Hsp40 bind with low
micromolar affinity to NTD1-155.
Hsp70 and Hsp40 bind to the FQNLF motif in cells. To validate
in cells the observations made in vitro HEK293T cells were
transfected with full length AR tagged with the FLAG epitope
(FLAG-AR) and its interaction with endogenous Hsp40 and
Hsp70 was assessed by proximity ligation assay (PLA). This
immunofluorescence-based technique is particularly useful for
detecting transient PPIs in cells where the putative complexes are
of intermediate or low stability and therefore unlikely to with-
stand the washing steps that are required for co-
immunoprecipitation experiments45. Briefly, the method relies
on the use of primary antibodies that recognize the two proteins
(e.g. AR and Hsp70), and on secondary antibodies that are
conjugated to complementary oligonucleotides. When the pro-
teins are in close proximity, these oligonucleotides hybridize and
are ligated to form a circular DNA template that can be amplified
by DNA polymerase and detected by fluorescence probes. The
PLA signals can therefore be detected by fluorescence microscopy
as red puncta in the PLA experiment.
Using this approach, we observed a clear interaction between
FLAG-AR and both Hsp40 and Hsp70 in the cytoplasm prior to
activation but found that DHT treatment induced an almost
complete loss of the interaction (Fig. 3a, c) combined with nuclear
translocation (Supplementary Fig. 4). These results agree with the
notion that activation of AR by DHT causes the dissociation of
the cytosolic complexes that AR forms with molecular chaperones
prior to nuclear translocation3,8. To test whether the interaction
detected by PLA occurs in cells via the region of sequence
containing the FQNLF motif detected by NMR, we repeated these
experiments using a version of FLAG-AR with the FQNLF motif
mutated to AQNAA (FLAG-AR-mut) and a deletion mutant,
where the region of sequence spanning residues 21 to 35, which
includes the FQNLF as well as adjacent similar VREVI motif, was
deleted (FLAG-AR-del). We observed that while FLAG-AR-mut
could still interact with both Hsp40 and Hsp70 (Supplementary
Fig. 5), the interaction of FLAG-AR-del with both molecular
chaperones was substantially weaker (Fig. 3a, c). These results
suggest that mutation of the three residues at the core of the
FQNLF motif is not sufficient to abolish the affinity for Hsp70 or
Hsp40, that instead requires the complete deletion of this motif
and the ca. 10 residues immediately flanking it. This result is
consistent with the 10-fold weakened affinity of the AQNAA
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Fig. 3 Removal of the FQNLF motif and flanking residues prevents the interaction of cytosolic AR with Hsp40 and Hsp70 in cells. a The interaction between
FLAG-AR as well as FLAG-AR-del with endogenous Hsp70 in the absence or presence of 1 nM DHT was studied in transfected HEK293T cells by PLA (n=
3). EV stands for empty vector, FLAG-AR/Hsp70 complexes appear as red dots and DAPI (blue) indicates the localization of nuclei. b Analysis by Western
blotting of the levels of FLAG-AR and FLAG-AR-del in transfected HEK293T cells in the absence or presence of 1 nM DHT (n= 3). β-actin immunoblot is
shown as a loading control. Log2 transformed values were used to assess differences using two-tailed unpaired t-tests and ***p < 0.001. c Assay equivalent
to that presented in a to study the interaction with the endogenous Hsp40 (n= 3). The scale bars in a, c represent 10 μm. Source data for the comparison
of protein levels shown in b are available as Source Data file
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mutant for Hsp70 observed in the NMR and FP experiments (see
Supplementary Fig. 3). It should be noted that our PLA
experiments were designed to detect the interaction of molecular
chaperones with the NTD of AR and are therefore unlikely to
report on whether they interact with the LBD. In addition, the
fact that both FLAG-AR-mut and FLAG-AR-del readily translo-
cate to the nucleus upon activation suggests that these variants
retain some early AR functions (Supplementary Fig. 4). Collec-
tively, these results confirm that, in cells, prior to activation by
androgens, the molecular chaperones Hsp40 and Hsp70 bind to
AR via a region of sequence including the motif FQNLF and the
residues flanking it.
Hsp70 and Hsp40 have both been implicated in turnover of
AR. To probe the role of their interaction with the FQNLF motif
in this process, we compared the levels of FLAG-AR-mut and
FLAG-AR-del with those of the wild type protein prior and
following to activation with DHT. We observed that mutation
and, especially, deletion of the FQNLF motif caused an increase in
basal AR levels in the absence of hormone (Fig. 3b, Supplemen-
tary Fig 5B). Also, recent studies have shown that disrupting AR’s
N/C interaction delays disease onset in a mouse model of
SBMA46. These studies utilized mice that expressed a mutant
form of the polyQ AR where the Phe residue of the FQNLF motif
was mutated to Ala. To determine whether this mutation had an
effect on the interaction between the AR NTD and molecular
chaperones, we carried out experiments with the equivalent
mutant of NTD1-155, named AQNLF-NTD1-155. An analysis of
the interaction by NMR showed that the AQNLF mutant
interacts in vitro with molecular chaperones with an affinity that
was indistinguishable from that of the WT (Supplementary
Fig. 6). Thus, our results confirm that amelioration of the SBMA
phenotype in mice expressing this mutant is likely due to a
weakening of the N/C interaction rather than an altered
interaction with molecular chaperones.
Hsp70 increases the solubility of the AR NTD. Because Hsp70
and Hsp40 are released from the NTD1-155 after addition of the
androgen dihydrotestosterone (DHT), the hormone-dependent
phenotype of SBMA and ligand-dependent aggregation of the
polyQ AR strongly suggest a protective role for these molecular
chaperones in limiting AR aggregation47–50. To investigate this
possibility by solution NMR, we analyzed the oligomerization
properties of the NTD1-155 construct by measuring 1H,15N-
HSQC spectra at two different concentrations, 125 and 450 μM at
278 K. NMR can be used to monitor concentration-dependent
oligomerization because the monomer-to-oligomer exchange
process contributes to NMR linewidths, such that the R2 15N
relaxation rates are increased51. In NTD1-155 we first confirmed
that the position of the backbone amide chemical shifts did not
change with concentration. Then, we measured the R2 15N
relaxation rates and found that some residues had higher values at
450 μM, when compared to 125 μM (Fig. 4a). A closer exam-
ination of these linewidth changes showed that the affected
residues were clustered into regions of locally high AABUF
values, suggesting that hydrophobicity could be the main driving
force of oligomerization. Indeed, the most affected region was
localized to the first 50 residues of the construct, with a maximum
in the FQNLF motif. This observation is conceptually equivalent
to that made by Wetzel and co-workers in huntingtin, in which it
was shown that the early stages of aggregation are not driven by
inter-molecular interactions involving the polyQ tract, but rather
by hydrophobic, coiled coil-like interactions in the sequence
flanking it at the N-terminus52,53. Further, these results raise the
intriguing possibility that binding of molecular chaperones to this
region of AR might directly suppress its oligomerization.
We then carried out NMR experiments to directly study
whether the interaction of Hsp70 with the NTD1-155 construct
influenced its solubility. For these experiments, we prepared
samples of NTD1-155 at 125 μM and added human Hsp70 at 1
molar equivalent, using the same conditions presented in Fig. 1,
and measured the corresponding 1H,15N-HSQC spectra as a
function of incubation time at 298 K. In the absence of chaperone,
we observed a progressive decay of signal intensity, so that after
6 days of incubation, ~25 % of the signal intensity was lost. This
signal decay was likely caused by formation of aggregates whose
size precluded their detection by NMR, as evident by the turbidity
of the samples over time. By contrast, the samples containing
Hsp70 did not show any decrease of signal intensity, suggesting
that the complex remained soluble (Fig. 4b). These results suggest
that molecular chaperones limit self-interactions between FQNLF
motifs in different AR NTD molecules, diminishing its oligomer-
ization and maintaining solubility.
Hsp70 increases AR solubility in vivo. A key prediction of these
studies is that chemical stabilization of the Hsp70 interaction
might limit aggregation of polyQ AR. Recent work has produced
chemical probes that significantly enhance Hsp70’s affinity for
disordered proteins54. Briefly, Hsp70 normally cycles through
rounds of ATP hydrolysis, with the ATP-bound state having
relatively poor affinity for substrate proteins and the ADP-bound
state having tight affinity55. These compounds, such as YM-1,
favor the ADP-bound state56, therefore stabilizing Hsp70’s
interactions. In addition, stabilizing this complex has been shown
to enhance turnover of some Hsp70 client proteins54. Thus, we
hypothesized that these compounds might limit polyQ AR
aggregation and potentially promote its turnover in SBMA
models.
To understand if Hsp70 modulators might have these favorable
activities, we first tested a small panel of them in PC12 cells that
stably express AR with an expanded polyQ tract encoded by 112
CAG repeats, termed AR112Q, under a tetracycline responsive
promoter57. In these cells, treatment with ligands, such as DHT
or the synthetic androgen metribolone (R1881), leads to nuclear
accumulation of misfolded polyQ AR, consistent with aggregation
after release of chaperones. SDS-insoluble polyQ-AR species can
be separated by centrifugation and visualized by western blot or
by filter trap assay (Supplementary Fig. 7). In our small-scale
screen, we found that two Hsp70 modulators, JG-84 and JG-98,
were the most potent in enhancing solubility of polyQ AR
(Supplementary Fig. 7A-D). Moreover, the active molecules
promoted clearance of both monomeric and aggregated polyQ
AR species (Supplementary Figs. 7D–F, 8), and were more
striking on polyQ AR than wild type AR (Supplementary Fig. 8).
Further analysis demonstrated that the more potent Hsp70
modulator, JG-98, increased polyQ AR ubiquitination and
enhanced degradation through the proteasome (Fig. 5a, b).
Notably, treatment with JG-258, a structural analog of JG-98 that
does not bind Hsp7058, does not change steady state polyQ AR
levels or alter polyQ AR ubiquitination (Supplementary Fig. 9).
We wondered whether these effects might occur because of an
HSF1 dependent stress response. To test this idea, we performed
western blots for three stress-inducible biomarkers: Hsp25,
Hsp40, and Hsp70. In treated cells, reduction of AR112Q
occurred without induction of heat shock proteins (Fig. 5c). In
contrast, the Hsp90 inhibitor, 17-AAG, strongly increased the
levels of these proteins (Fig. 5c), consistent with induction of an
HSF1 dependent stress response. Additionally, JG-98 did not
affect levels of Hsp90 client proteins in their native conforma-
tions, such as Akt and Erk (Fig. 5c), both of which are degraded
following treatment with Hsp90 inhibitors. Finally, recent work
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has suggested that combining Hsp70 modulators with Hsp90
inhibitors might further promote AR clearance12. Consistent with
this notion, we found that combinations of an Hsp70 modulator,
JG-98, with an Hsp90 inhibitor, 17-AAG, produced robust polyQ
AR clearance (Fig. 5d). Together, these findings supported a
model in which stabilizing the Hsp70-AR interaction enhances
the solubility and clearance of AR.
To test this idea in an animal model of SBMA, we turned to an
analog of the Hsp70 modulators, JG-294, that is tolerated in mice
and has well-studied pharmacokinetics58. Before proceeding into
animals, we first confirmed that JG-294 could induce degradation
of polyQ AR in PC12 cells expressing AR112Q. Indeed, treatment
with JG-294 yielded a significant reduction in the levels of
AR112Q, as detected by western blot and immunofluorescence
microscopy (Fig. 6b, c). Next, we tested whether JG-294 might
have activity in a well-characterized mouse model of SBMA
generated by gene targeting (AR113Q mice)50,59. In this model,
like the cell-based system, AR113Q accumulates as SDS-insoluble
high molecular weight species in skeletal muscle from mutant
males. Strikingly, treatment with JG-294 for two weeks (i.p., at 3
mg kg−1 every other day) reduced levels of both high molecular
weight and monomeric polyQ AR when compared to the vehicle
treated controls (Fig. 7a, b, d, e). These changes occurred without
alteration in AR mRNA levels (Fig. 7c), consistent with the notion
that JG-294 promoted polyQ-AR clearance. Notably, as in cell
culture, these effects were distinct from those triggered by
treatment with an Hsp90 inhibitor, as no induction of Hsp70 or
loss of client proteins in their native conformation were seen
following treatment with JG-294 (Fig. 7e). Together, these results
suggest that stabilizing the interactions between Hsp70 and AR
may be a viable therapeutic strategy for SBMA. Collectively, our
findings support a model in which Hsp70 directly binds to the
NTD of AR as a sensor for misfolding and aggregation.
Discussion
We show here that AR activation seems to be governed, in part,
by a competition between chaperones and the AF-2 region for
binding to a region of the NTD including the FQNLF motif.
Specifically, inter-molecular interactions with Hsp70 and Hsp40
appear to prevent activation of AR by sequestering the FQNLF
motif while intra-molecular interactions of this same region with
AF-2 in the LBD are required for activation. We find that the
relative strength of these competing PPIs is regulated by androgen
binding to the LBD, which stabilizes the AF-2, and, therefore,
promotes its interaction with the FQNLF motif and displaces the
chaperones.
What is the role of the Hsp40 in this process? Hsp40 and
Hsp70 normally work in concert and, by analogy with other
systems, we propose that Hsp40 binds AR first and then recruits
Hsp70 via its conserved J-domain. In cells, binding of the J-
domain stimulates ATP cycling by Hsp7060, which creates the
tight affinity, client-chaperone complex. Therefore, we expect that
Hsp40 would assist Hsp70 by both localizing it to AR and
accelerating its catalytic cycle. This is important because our
in vitro experimental platforms, while aimed at investigating the
equilibrium properties of the system in the absence of nucleotide,
likely underestimate the effective affinity for the NTD. Moreover,
there are more than 45 proteins in the Hsp40 family in humans,
so the relevant subset for AR homeostasis is not yet clear.
One of the interesting implications of this model is that the
structure of the FQNLF motif itself might switch when bound to
either the chaperones or AF-2. Specifically, it is known that the
FQNLF motif is helical after binding to AF-2 and activation, yet
we have shown that it can interact with the canonical groove of
Hsp70, likely in an extended conformation. Thus, these studies
suggest that (at least) two sets of competing PPIs, in addition to a
local conformational switch, underlie the activation of AR. Fur-
ther experiments will be needed to understand whether there is a
link between these molecular events and the broader changes that
occur during nuclear translocation and transcriptional activity of
AR. Additionally, it has previously been observed that Hsp70
binds to the LBD of SHRs9 and it is not yet known whether the
N-terminal mechanism presented here is connected to other
chaperone-mediated processes at the LBD. Despite these
remaining questions, this molecular view of AR dynamics and
PPIs has a number of interesting implications.
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First, these results also provide insight into how Hsp70 and
Hsp40 regulate the solubility of AR. We noted that Hsp70 pre-
vents the oligomerization of AR’s NTD1-155 (Fig. 4), likely by
directly encumbering the FNQLF motif and surrounding regions
that are hydrophobic and aggregation-prone. We speculate that
this activity, combined with the fast turnover of AR prior to
androgen binding, conspire to minimize the propensity of the
receptor to oligomerize and aggregate by preventing exposure of
the most aggregation-prone sequence while simultaneously
keeping its concentration low in the cytoplasm. In this scenario,
molecular chaperones would contribute, by acting as holdases, to
keeping the receptor monomeric and at low concentration i.e.
primed for rapid activation by androgens without compromising
solubility. Putting these mechanisms together, it seems elegant to
propose that Hsp70’s interactions with the FQNLF motif might
create a three-way tug-of-war, in which the chaperone competes
for both: (a) proper intra-molecular contacts with AF-2 and (b)
inter-molecular contacts between the FQNLF motifs of two AR
molecules, leading to aggregation. The relative affinities of these
competing PPIs likely balances the activation of the receptor and
governs its unnatural aggregation in SBMA (Fig. 8).
Based on the experiments with Hsp70 modulators, we propose
that this delicate balance of PPIs also regulates AR turnover. In
other systems, such as microtubule-associated protein tau
(MAPT) and X-linked inhibitor of apoptosis (XIAP), tight
binding of Hsp70 has been observed to promote turnover54,61.
Similarly, prolonged interactions with Hsp70 seem to favor
turnover of polyQ-expanded AR. Thus, more broadly,
Hsp70 seems to use a dwell time method to discriminate between
damaged and healthy proteins (Fig. 8). In the case of AR, the
incorrect decision to release polyQ AR may partially underlie
protein aggregation in SBMA, such that chemical perturbations
with JG-98 or JG-294, can partially re-balance the system and
promote turnover. In this model, it is striking that the same
chaperone that governs receptor activation and solubility is also
tasked with monitoring its quality control.
Notably, numerous functions essential for cell viability, ranging
from energy and ion homeostasis to axonal transport and gene
expression, are disrupted by misfolded proteins that cause age-
dependent protein aggregation neurodegenerative disorders,
including SBMA62,63. Alterations in these multiple pathways
likely contribute to toxicity in a cumulative manner, suggesting
that therapeutically targeting any one of them is likely to yield
incomplete rescue. In contrast, decreasing levels of mutant pro-
teins such as the polyQ AR has emerged as an attractive ther-
apeutic strategy to target the proximal mediator of disease
pathogenesis.
In this regard, our findings have implications for potential new
therapies. Many efforts to develop chaperone-targeted therapies
for protein aggregation diseases have focused on inhibition of
Hsp90. Our data indicate that targeting Hsp70 may have sig-
nificant advantages. For example, Hsp70 activation favors the
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removal of misfolded proteins rather than client proteins in their
native or near-native states11,12,64. This distinction suggests that
Hsp70-targeted small molecules may avoid some of the toxic
effects of Hsp90 inhibitors, which promote degradation of hun-
dreds of client proteins in their native conformations, some of
which might be needed for normal cellular functions. Similarly,
the other major strategy for activating chaperone function is to
target the stress response transcription factor, HSF1. However,
experimental evidence suggests that chronic activation of HSF1
may promote toxicity by triggering a maladaptive stress response
that is present in many protein-folding diseases65. In contrast, we
found that targeting Hsp70 does not lead to activation of stress-
responsive proteins. Thus, these results suggest that Hsp70 may
be a good target for the treatment of SBMA. In addition, AR has
been implicated in other diseases, such as prostate cancer. Indeed,
recent studies have established that the same Hsp70-targeted
small molecules promote clearance of an AR splice variant that is
associated with prostate cancer and lacks the C-terminal LBD13.
Together, these observations point to Hsp70 as a promising target
in multiple AR-associated diseases. Such strategies may take
advantage of the normal protein quality control functions of this
chaperone, which are already evolved to regulate AR solubility
and degrade the damaged receptor.
Methods
Protein expression and purification. The genes codifying for NTD1-155 and its
variants were purchased from GeneArt and cloned in a pDEST-HisMBP vector
(Addgene: #11085) whereas that codifying for NTD144-45029 was instead cloned into
a Gateway pDEST17 vector (Invitrogen). Expression of the resulting genes led to
fusion proteins containing a His6 tag, a maltose binding protein (MBP) moiety for
NTD1-155 and its variants and a motif recognized by the tobacco etch virus (TEV)
protease. The His6 tag was used as a purification tag, whereas MBP was used to
increase the solubility of NTD1-155 and its variants. 15N labeled protein expression
was carried out in Rosetta (DE3) pLysS E. coli competent cells Novagen (Merck),
grown in Luria Broth (LB; Melford) at 37 °C at 220 r.p.m. until the value of OD600
was 0.7, centrifuged at 2000 G for 20 min, then washed in MOPS buffer (3-(N-
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morpholino) propanesulfonic acid (200 mM), sodium acetate (50 mM), EDTA
(10 mM), pH 7.0) devoid of nitrogen sources and rapidly centrifuged at 5000 G for
10 minutes. Cells were then resuspended in MOPS media containing 15NH4Cl as a
nitrogen source (Eurisotope), induced with 0.5 mM Isopropyl β-D-1-thiogalacto-
pyranoside (IPTG, Sigma) for 4 hours at 28 °C, harvested by centrifugation and
resuspended in core buffer (50 mM sodium phosphate, 500 mM NaCl, 5% (v/v)
Glycerol, 1 mM 2-Mercapto-ethanol, pH 8.0). A HisTrap HP 5ml column (GE
Healthcare) was used to purify the proteins, which were eluted by an imidazole
gradient (final composition: 500 mM imidazole, 50 mM sodium phosphate,
500 mM NaCl, 5% Glycerol, 1 mM βMercapto-ethanol, pH 8.0), followed by a size
exclusion step carried out in a Superdex HighLoad S200 26/60 column (GE
Healthcare) equilibrated in a buffer with the following composition: 500 mM NaCl,
12 mM sodium phosphate, 5% glycerol, 1 mM DTT, pH 7.5. To separate NTD1-155
from its tags, the pure fusion proteins were then incubated with His6-tagged TEV
protease for 16 hours at 4 °C by dialysis against a buffer containing 20 mM sodium
phosphate, 100 mM NaCl, and 0.5 mM EDTA, pH 8.0. The product of proteolytic
cleavage was separated from the tags by Ni2+ affinity chromatography, employing
a buffer containing 8M urea (500 mM imidazole, 50 mM sodium phosphate,
100 mM NaCl, 8 M urea, pH 8.0) to prevent the aggregation of the cleaved AR in
the column. Finally, the cleaved proteins were stored at −80 °C.
Full length, human Hsp70 (HSPA1A) and Hsp40 (DnaJA2) constructs were
transformed into BL21(DE3) cells and single colonies were used to inoculate
Terrific Broth (TB) medium containing ampicillin (50 µg mL−1). Cultures were
grown at 37 °C for 5 h, cooled to 20 °C and induced overnight with 200 μM IPTG.
DnaJA2 and Hsp70 (SBD) (residues 394–540) were purified using a Ni2+-NTA
column, followed by overnight TEV cleavage of the His tag and gel filtration on a
Superdex S200 (GE Healthcare). Hsp70 was purified using a Ni2+-NTA column,
followed by overnight TEV cleavage and subjection to an ATP agarose column.
Hsp70 was eluted with ATP and dialyzed to remove excess nucleotide. This
purification method provides Hsp70 in its ADP-bound state, based on partial
proteolysis. A truncated form of Hsp70SBD (HSPA1A) was used for the FP studies,
which encompasses residues 394-509, was purified in a similar way.
NMR Sample preparation. The protein solutions stored at −80 °C were
thawed and dialyzed for 16 h at 4 °C against a phosphate buffer (sodium phosphate
(20 mM), tris(2-carboxyethyl)phosphine (TCEP, 1 mM), pH 7.4). Finally, 10% D2O
and 0.015 mM DSS were added to the samples.
Acquisition and analysis of NMR spectra. Two-dimensional 1H,15N-HSQC
NMR experiments were recorded at 5 °C on a Bruker 600 or 800MHz spectrometer
equipped with cryogenic probes. Spectra were processed with NMRPipe66 and
analyzed using CcpNMR Analysis67. The NMR samples used for the experiments
reported in Fig. 1, Supplementary Figs. 1 and 5 contained 33 µM 15N single-
labelled NTD1-155 protein and either 16.5 µM or 33 μM unlabeled Hsp70 and
Hsp40 in 20 mM phosphate buffer, pH 7.4, 1 mM TCEP, and 10% (v/v) D2O. The
NMR samples used for the experiments shown in Supplementary Fig. 1 were
equivalent to those used for the experiments shown in Fig. 1, but contained
NTD144-450 instead of NTD1-155.
The NMR samples used for the experiments reported in Fig. 4a contained 125
and 450 µM 15N single-labelled NTD1-155 constructs and those used for the
experiments reported in Fig. 4b contained 125 µM 15N single-labelled NTD1-155
constructs and 125 μM unlabeled Hsp70. The 15N R2 rates of NTD1-155 were
measured with 10 different relaxation delays (t) and fit to the equation I ¼
IoexpðR2tÞ and only the values of R2 determined with less than 5% error were
considered sufficiently reliable for the analysis shown in Fig. 4a. The ratio of signal
intensities shown in Fig. 4b corresponds to the total signal intensity of the signals
that are not affected by chaperone binding (Fig. 1) measured at a given time
divided by that measured after 1 day of equilibration.
Fluorescence polarization assays. For competition FP studies, 2 μM Hsp70SBD
and 25 nM FAM-LVEALY (Anaspec) were incubated with varying concentrations
of AR protein for 30 min at room temperature in assay buffer (100 mM Tris,
20 mM KCl, 6 mM MgCl2 pH 7.4). After incubation, fluorescence polarization was
measured (excitation: 485 nm emission: 535 nm) using a SpectraMax M5 plate
reader. In the case of the FAM-NRLLLTG tracers, 12 μM Hsp70SDB, and 25 nM
tracer were used and experiment was performed in a similar manner. These
experiments were repeated in duplicate and repeated on three independent days.
Isothermal Titration Calorimetry. The NTD1-155 proteins, as well as Hsp70SBD or
Hsp40, were dialyzed overnight against ITC buffer (25 mM HEPES, 5 mM MgCl2,
10 mM KCl pH 7.5). Concentrations were determined using a BCA Assay (Thermo
Fisher Scientific), and the experiment was performed with a MicroCal ITC200
(GE Healthcare) at 25 °C. AR protein (100–200 μM) in the syringe was titrated into
a 10–20 μM cell solution of Hsp70 (SBD) protein. Calorimetric parameters were
calculated using Origin 7.0 software and fit with a one or two-site binding model.
Experiments were performed in duplicate and repeated twice on two
independent days.
Cell culture and transfection. Human embryonic kidney 293 T cells
(HEK293T cells) were obtained from ATCC (CRL-3216) and maintained in DMEM
containing 4.5 g L−1 glucose (Glutamax, Gibco) supplemented with 10% (v/v) char-
coal stripped calf serum (Gibco) and antibiotics. Cells were cultured in a humidified
atmosphere containing 5% CO2 at 37 °C. Transient transfection of HEK293T cells was
performed with polyethylenimine (PEI) (Polysciences) at a ratio of 1 µg DNA to 3 µl
PEI to express androgen receptor tagged with the FLAG epitope (FLAG-AR), the
mutated version (FLAG-mut) and the version lacking the region of sequence targeted
by Hsp40 and Hsp70 in the NMR experiments (FLAG-del).
PC12 cells expressing tetracycline-inducible AR112Q (gift of Diane Merry,
Thomas Jefferson University) were characterized previously57. Cells were
maintained in phenol red-free DMEM (21063-029, Invitrogen) supplemented with
5% charcoal stripped fetal calf serum (Thermo Scientific Hyclone Products), 10%
charcoal stripped horse serum (Invitrogen), G418 (Gibco) and Hygromycin B
(Invitrogen). When indicated, cells were transfected using Lipofectamine 2000
(Life Technologies) or the Neon transfection system (Thermo Scientific) to express
human CHIP and HA-His-ubiquitin (gifts from Dr. Yoichi Osawa, Univ. of
Michigan). AR expression was induced with 0.5 µg mL−1 doxycycline (Clonetech)
and activated by treatment with the synthetic androgen R1881. Lactacystin was
from Sigma-Aldrich (L6785) and 17-AAG was from LC Laboratories (A-6880).
Antibodies and reagents. For Western Blot analyses the following antibodies were
used: anti-β-actin-HRP (ab8224, 1:10000) (Abcam), rabbit-anti-FLAG (F7425,
1:2000), and mouse-anti-FLAG M2 (F1804, 1:2000) (Sigma), mouse-anti-HSP70/
72 (ADI-SPA-810) and rabbit-anti-HSP40 (ADI-SPA-400-D) (Enzo Life Science).
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Fig. 8 Roles of Hsp40 and Hsp70 in AR homeostasis. Scheme describing how Hsp40 and Hsp70, by interacting with a region of sequence containing the
FQNLF motif, regulate the activity, cellular concentration and solubility of AR
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Additional primary antibodies were used against Akt (C6E7; Cell Signaling
Technology), ERK1/2 (9102, Signaling Technology), GAPDH (NB-600-502; Novus
Biologicals), HSP90 (H114, sc7947; Santa Cruz Biotechnology), CHIP (PA5-32046,
Thermo Scientific, Pierce), HA (MMS-101R, Covance, Biolegend), HSP25 (ADI-
SPA-801-488; Enzo Life Science), and HSP70 (ADI-SPA-812; Enzo Life Science).
HRP conjugated secondary antibodies were from Bio-Rad (170-6515, 170-6516).
For immunofluorescence the following primary antibodies were used: rabbit-anti-
FLAG (F7425, 1:200), mouse-anti-FLAG M2 (F1804, 1:200) (Sigma), AlexaFluor
conjugated secondary antibodies were from Life Technologies (A11072, 1:300).
Mounting medium with DAPI (H-1200, 1:500) was from Vector Labs. For
immunoprecipitation, pull down was performed with protein A–agarose beads
(Santa Cruz Biotechnology) and the anti-AR antibody (PG21; Millipore).
Western blotting. Cells were washed and harvested in PBS, lysed in RIPA buffer
(Technova) containing phosphatase and protease inhibitors (Roche). Lysates were
centrifuged at 15000 g to separate soluble and pellet fractions. Total protein was
quantified using BCA assay (Pierce Biotechnology). Proteins were resolved by 7.5
or 15% SDS-PAGE, transferred to PVDF or nitrocellulose membranes, and probed
with specific antibodies.
Filter retardation assay was performed by sample filtration through a 0.2 μm
cellulose acetate membrane (Whatman, GE Healthcare) using a slot-blot apparatus.
For ubiquitination studies, cells were homogenized in buffer (0.025 M Tris, 0.15
M NaCl, 0.001 M EDTA, 1% NP-40, 5% glycerol, pH 7.4) containing protease
inhibitors and 5 mM N-ethylmaleimide (Sigma-Aldrich). Lysates were incubated
on a rotator at 4 °C for 2 h with AR antibody or non-immune rabbit IgG (Santa
Cruz Biotechnology). Prewashed protein A–agarose beads were added, and samples
were incubated for 1 additional hour at 4 °C. Protein-antibody-bead complexes
were washed 6 times in buffer, and proteins were eluted by boiling in SDS-loading
buffer for 5 min at 100 °C. Samples were then resolved on by 7.5% SDS-PAGE.
Images of uncropped and unprocessed scans of blots are provided as Source
Data files.
Agarose gel electrophoresis for resolving aggregates was performed as
previously described68. Briefly 150 µg total protein was loaded to 1.5% agarose gels
(375 mM Tris buffer, pH 8.6; 0.1% SDS) and electrophoresed at 100 V until the dye
front had reached the bottom of the gel. Transfer of proteins was performed using a
semi-dry transfer apparatus to PVDF membranes.
Immunofluorescence. For immunofluorescence, cells were seeded on sterilized
12 mm microscope coverslips, fixed 15 min in 4% paraformaldehyde at room
temperature and permeabilized in ice-cold methanol for 10 min. Cells were then
washed, blocked with PBS containing 2% bovine serum albumin for one hour at
room temperature and incubated with the corresponding primary antibody diluted
in blocking solution for one hour. After washing with PBS, samples were further
incubated with the corresponding secondary antibodies for one hour. DAPI was
used to label DNA and the coverslips were washed, air-dried and mounted on
slides using Prolong Gold antifade mountant (Life technologies). 6 μm cryosections
of muscle were fixed in methanol. Slides were stained, mounted, and imaged by
confocal microscopy (Olympus FV 500 or Nikon A1). Nuclear signal intensity was
quantified by CellProfiler.
Proximity ligation assay. The Duolink in situ Proximity ligation (PLA) kit (Olink
Bioscience) was used for the detection of protein–protein interactions according to
the manufacturer’s instructions45. The assay is based on the simultaneous binding
of two antibodies to the proteins of interest and makes use of a proximity ligation
technique combined with an amplification reaction to detect the antibodies
whenever they are less than 30 nm apart. HEK293T cells were grown and trans-
fected as indicated on 12 mm microscope coverslips (Thermo). Cells were fixed in
PBS containing 4% paraformaldehyde for 15 min and permeabilized with methanol
for 5 min. Fixed cells were blocked in PBS containing 2% BSA (Sigma) for an hour
and then incubated with the indicated antibodies against Hsp70 (ADI-SPA-810,
1:100), Hsp40 (ADI-SPA-400-D, 1:100) (Enzo Life Science) and FLAG (M2, F1804
and F7425, both 1:50) (Sigma). Samples were subsequently incubated for 1 h at
37 °C with secondary antibody PLA with and without probes for mouse and rabbit
(Sigma), and then for 30 min at 37 °C with a ligation solution to ligate the two PLA
probes and form a circular DNA template. A rolling-circle amplification was then
performed by incubating the cells for 100 min at 37 °C with the amplification
solution. The amplicons generated are recognized by fluorescent oligonucleotides
present in the amplification solution. Nuclei were stained with DAPI and the
coverslips were washed, air-dried and mounted on slides using Prolong antifade
mountant (Life Technologies). Cells were analyzed with a ×63 objective on a Leica
SP5 confocal microscope. Images were presented as maximal projection of z-stacks
by using Fiji.
AR113Q mice. AR113Q knock-in mice were generated using exon 1-specific gene
targeting50,59, backcrossed to C56BL/6 (≥10 generations), and housed in a specific
pathogen-free facility on a 12-h light/dark cycle with chow and water ad libitum.
For analysis, AR113Q males were used at 3 months of age and randomly assigned
to treatment groups. JG-294 was dissolved in 70% propylene glycol (W294004,
Sigma-Aldrich) and 30% PBS (pH 7.4, Life Technologies), heated to 95 °C to
dissolve compound, aliquoted and frozen. Mice received intraperitoneal injections
(3 mg kg−1) every other day for 2 weeks. 17-DMAG (S1142, Selleckchem) was
dissolved in 1% DMSO (D2650, Sigma-Aldrich), 30% polyethylene glycol (202371;
Sigma-Aldrich) and 1% Tween80 (P4780; Sigma-Aldrich), and administered by i.p.
injection (10 mg kg−1) every other day for 2 weeks. At the end of treatment, mice
were euthanized and quadriceps were harvested and flash frozen in liquid nitrogen
or mounted on OCT (Tissue-Plus, Fisher Health Care) for cryosectioning. For
western blot, lysates were obtained by homogenizing tissue in RIPA containing
phosphatase and protease inhibitors. All procedures involving mice were approved
by the University of Michigan Committee on Use and Care of Animals
(PRO00008133) and conducted in accordance with institutional and federal ethical
guidelines for animal testing and research.
Quantitative RT-PCR. Total RNA was extracted from mouse quadriceps muscles
using Trizol (Sigma-Aldrich). cDNA was synthesized from extracted RNA using
the High Capacity cDNA Reverse Transcription Kit (Applied Bio Systems).
Quantitative PCR was carried out on a 7500 Real-Time PCR System (Applied
Biosystems) using FastStart TaqMan Probe Master Mix (Roche) and gene specific
primers for AR (universal probe library #58, Roche; 5′ primer: ccagtcccaattgtgtcaaa;
3′ primer: tccctggtactgtccaaacg) and Cpsf2 (Mm00489754_m1, Applied Biosys-
tems). Relative AR expression was determined by the standard curve method and
normalized to Cpsf2.
Statistics. Statistical significance was determined by analyzing data sets using
unpaired Student’s t-test, one-way ANOVA with Tukey’s multiple comparison test
or two-way ANOVA with Bonferroni or Niewman–Keuls multiple comparison test
in Prism6 (GraphPad). Differences between mean values were defined as significant
at p < 0.05.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
The source data underlying the quantifications shown in Figs. 2A, 3B, 4B, 5A, 5D, 6B, 6C,
7B, 7C, 7E, and Supplementary Figs. 3A, 7F, and 9A are available as Source Data files and
any other data is available from the corresponding authors upon reasonable request.
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